Claris Lifesciences, one of the largest sterile injectables pharmaceutical companies in India, surged on Wednesday after it received USFDA report stating it's finished dosage plant and API plant as acceptable.

Shares of the company are trading at Rs 170.05, up Rs 6.85, or 4.20% at the Bombay Stock Exchange (BSE) on Wednesday at 1:10 p.m.

The scrip has touched an intra-day high of Rs 175.05 and low of Rs 166. The total volume of shares traded at the BSE is 196,465.